Vigabatrin (Sabril)
vigabatrin — irreversible GABA-transaminase inhibitor (γ-vinyl-GABA)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Refractory complex partial seizures (CPS) | ≥2 years of age | Adjunctive therapy (not first-line) | FDA Approved |
| Infantile spasms (IS) | 1 month to 2 years of age | Monotherapy | FDA Approved |
Vigabatrin occupies a unique position among antiseizure medications as an irreversible enzyme inhibitor with a mechanism fundamentally different from all other ASMs. Its two FDA-approved indications reflect very different clinical scenarios. For refractory complex partial seizures, vigabatrin is strictly a last-resort adjunctive agent reserved for patients who have failed multiple alternatives, because the risk of permanent vision loss precludes its use as an early-line therapy. For infantile spasms, vigabatrin has a more prominent role and is considered one of three first-line options alongside ACTH and oral corticosteroids, particularly in patients with tuberous sclerosis complex (TSC) where response rates are especially high. Due to the risk of permanent vision loss, vigabatrin is available only through the Vigabatrin REMS Program, requiring certified prescribers and pharmacies, patient enrollment, and mandatory periodic vision monitoring.
Succinic semialdehyde dehydrogenase (SSADH) deficiency: Vigabatrin is used in this rare inborn error of GABA metabolism to lower accumulating GHB levels by inhibiting GABA-transaminase. Evidence quality: Low (case series; orphan disease).
Tuberous sclerosis complex (TSC) — seizure types beyond infantile spasms: Some evidence supports vigabatrin for focal seizures in TSC patients of various ages, given the particularly high response rate in this population. Evidence quality: Moderate.
Dosing
Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Refractory CPS — adults (≥17 years) | 1,000 mg/day (500 mg BID) | 3,000 mg/day (1,500 mg BID) | 3,000 mg/day (6,000 mg/day has no additional benefit) | Increase by 500 mg/day weekly; taper by 1,000 mg/day weekly when discontinuing Withdraw if no substantial benefit within 3 months |
| Refractory CPS — pediatric 10–15 kg | 350 mg/day | 1,050 mg/day | 1,050 mg/day | All pediatric doses given as 2 divided doses; increase weekly >60 kg: use adult dosing |
| Refractory CPS — pediatric >15–20 kg | 450 mg/day | 1,300 mg/day | 1,300 mg/day | Taper by one-third every week for 3 weeks when discontinuing |
| Refractory CPS — pediatric >20–25 kg | 500 mg/day | 1,500 mg/day | 1,500 mg/day | Taper by one-third every week for 3 weeks when discontinuing |
| Refractory CPS — pediatric >25–60 kg | 500 mg/day | 2,000 mg/day | 2,000 mg/day | Taper by one-third every week for 3 weeks when discontinuing |
| Infantile spasms — 1 month to 2 years | 50 mg/kg/day (25 mg/kg BID) | Titrate by 25–50 mg/kg/day every 3 days | 150 mg/kg/day (75 mg/kg BID) | Monotherapy; use oral solution reconstituted to 50 mg/mL; withdraw if no substantial benefit within 2–4 weeks Taper by 25–50 mg/kg every 3–4 days when discontinuing |
| Renal impairment — adults and ≥2 years | Mild (CrCl >50–80): decrease dose 25% | Moderate (CrCl >30–50): decrease 50% | Severe (CrCl >10–30): decrease 75% | Primarily renally eliminated; no data on dose adjustment in infants with renal impairment | ||
The risk of permanent vision loss increases with cumulative dose and duration of exposure, and there is no dose or exposure known to be free of risk. The FDA PI mandates using the lowest dosage and shortest exposure consistent with clinical objectives. In refractory CPS, vigabatrin must be withdrawn if no substantial benefit is observed within 3 months. In infantile spasms, treatment should be withdrawn within 2–4 weeks if no response is seen. Patient response and continued need for treatment must be periodically reassessed throughout therapy.
Unlike most ASMs, monitoring vigabatrin plasma concentrations does not guide dosing. This is because vigabatrin is an irreversible enzyme inhibitor — its antiseizure effect depends on the rate of new GABA-transaminase synthesis (requiring several days) rather than on the instantaneous drug concentration. The plasma half-life of 5–8 hours dramatically understates the duration of pharmacological effect, which persists for days after the drug has been eliminated. Dose adjustments should be based on clinical response, not plasma levels.
Pharmacology
Mechanism of Action
Vigabatrin is a structural analogue of GABA that functions as an irreversible, mechanism-based inhibitor of GABA-transaminase (GABA-T), the enzyme responsible for the catabolism of the inhibitory neurotransmitter GABA. By permanently inactivating GABA-T, vigabatrin causes a sustained increase in synaptic and extrasynaptic GABA concentrations throughout the brain. The drug is supplied as a racemic mixture, but only the S(+)-enantiomer is pharmacologically active. Because the enzyme inhibition is irreversible, the pharmacological effect persists until new GABA-T enzyme is synthesized, a process that takes several days. This means the antiseizure duration of effect dramatically outlasts the drug's presence in plasma, making the plasma half-life a poor guide to dosing or efficacy. The resulting elevation of inhibitory GABAergic tone is effective across a broad range of seizure types but is particularly potent against infantile spasms, especially in the context of tuberous sclerosis complex.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Essentially complete oral absorption (~100%); Tmax 1–2 h (adults), ~2.5 h (infants); food decreases Cmax by 33% but does not alter AUC; linear pharmacokinetics from 0.5–4 g | May be given with or without food; food does not affect total drug exposure. Both tablet and oral solution formulations are bioequivalent |
| Distribution | Vd ~0.8 L/kg; no plasma protein binding (0%); enters CSF (CSF levels ~10% of plasma at 6 h post-dose) | Zero protein binding means no protein-displacement drug interactions and no binding-related PK variability in hypoalbuminemic patients. Wide tissue distribution |
| Metabolism | Not significantly metabolized; mild inducer of CYP2C9; no active metabolites | Minimal hepatic metabolism explains the lack of CYP-mediated drug interactions. CYP2C9 induction likely accounts for 16–20% decrease in phenytoin levels seen with co-administration |
| Elimination | Plasma t½ 5–8 h (adults), ~5.7 h (infants); ~70% excreted unchanged in urine; renal clearance is the primary elimination pathway; hemodialysis reduces plasma levels by 40–60%; linear kinetics; little accumulation with repeated dosing | Short plasma half-life is clinically misleading — pharmacological effect persists for days due to irreversible GABA-T inhibition. Dose reduction essential in renal impairment. Plasma level monitoring is not useful for guiding therapy |
Side Effects
The adverse effect profile of vigabatrin is dominated by the risk of permanent, irreversible visual field loss — an effect so significant that it carries an FDA Black Box Warning and mandates a REMS program for distribution. Beyond vision loss, the controlled trial data in adults show somnolence (24% vs 10% placebo), fatigue (28% vs 15%), dizziness, and weight gain as the most common treatment-emergent effects. In pediatric CPS patients, weight gain is the predominant adverse effect (47% gained ≥7% body weight vs 19% placebo).
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Fatigue | 28% vs 15% placebo (adult CPS) | Most commonly reported adverse effect; dose-related; advise against driving or operating machinery until familiar with effects |
| Somnolence | 24% vs 10% placebo (adult CPS) | Dose-related; may be additive with other CNS depressants; less prominent in pediatric CPS trials (6% vs 5%) |
| Weight gain (≥7% of baseline) | 17% vs 8% placebo (adults); 47% vs 19% (pediatric CPS) | Not related to edema; mean weight gain 3.5 kg vs 1.6 kg (placebo) in adults; long-term effects unknown; monitor weight at each visit |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Blurred vision | ≥5% over placebo (adult CPS) | Most common visual symptom reported; distinct from the visual field constriction in the Black Box Warning; may or may not indicate retinal damage |
| Dizziness | ≥5% over placebo (adult CPS) | Dose-related CNS effect |
| Abnormal coordination / tremor | ≥5% over placebo (adult CPS) | Cerebellar/motor effects; assess gait at visits |
| Anemia | 6% vs 2% placebo (adults) | Mean hemoglobin decrease ~3% vs 0% placebo; monitor for symptoms; rarely clinically significant |
| Peripheral edema | 2% vs 1% placebo (adults) | Not associated with cardiovascular deterioration or hepatic/renal dysfunction |
| Peripheral neuropathy | 4.2% (pooled); 1.4% vs 0% placebo (controlled) | Numbness/tingling in toes or feet, decreased vibration sense; reversibility not established |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Permanent bilateral concentric visual field constriction (BLACK BOX) | ≥30% of adults; poorly characterized in children | Unpredictable: weeks to years after initiation | Baseline vision assessment within 4 weeks; every 3 months during therapy; 3–6 months after discontinuation. Perimetry recommended in cooperative patients; ERG/OCT as adjuncts. Irreversible once detected. Consider discontinuation if vision loss documented. REMS mandatory |
| Decreased visual acuity (central retinal damage) | Occurs in some cases in addition to visual field loss | Variable | Central retina can also be damaged; visual acuity testing should be part of monitoring; irreversible |
| MRI abnormalities in infants (T2 signal changes) | 22% of vigabatrin-treated infants vs 4% other therapies | During treatment (infants with IS) | Symmetric T2 signal in thalamus, basal ganglia, brainstem, cerebellum; generally resolves with discontinuation; clinical significance of long-term sequelae unknown |
| Intramyelinic edema (neurotoxicity) | Observed in animal studies at therapeutic doses; reported in postmortem infant examinations | During treatment | Vacuolation in brain white matter seen in rats, mice, dogs, possibly monkeys; no established no-effect dose in rodents or dogs; MRI monitoring in infants recommended |
| Suicidal behavior and ideation | AED class effect (RR 1.8 vs placebo) | As early as 1 week | AED class warning; monitor for depression, mood changes, suicidal ideation at each visit |
Vigabatrin causes permanent bilateral concentric visual field constriction in 30% or more of adult patients. Severe cases manifest as tunnel vision to within 10 degrees of fixation, which can be functionally disabling. The onset is unpredictable — from weeks to years — and symptoms are unlikely to be recognized before loss is severe. Vision loss is irreversible once detected, and may worsen even after drug discontinuation. The mechanism is attributed to retinal toxicity via taurine depletion. This risk fundamentally defines vigabatrin's clinical positioning: it should only be used when benefits clearly outweigh this serious risk, and the lowest dose for the shortest possible duration must always be employed.
Drug Interactions
Vigabatrin has a remarkably clean drug interaction profile compared to older enzyme-inducing ASMs. It undergoes minimal hepatic metabolism, has zero protein binding, and does not induce or inhibit most CYP enzymes. The primary interaction of clinical relevance is a modest reduction in phenytoin levels, likely mediated by mild CYP2C9 induction. The FDA PI also notes that vigabatrin decreases amino acid transaminase (AST and ALT) laboratory values as a pharmacodynamic effect of GABA-T inhibition, which can mask detection of hepatic injury from other causes.
Monitoring
-
Vision Assessment
Baseline (within 4 weeks of start); every 3 months during therapy; 3–6 months after discontinuation
Routine MANDATORY per REMS. Perimetry (preferably automated threshold visual field testing) in cooperative patients. Consider ERG, OCT, or other methods for patients who cannot undergo perimetry. Includes infants where vision assessment should be individualized (visual acuity and visual field when possible). Vision loss may occur or worsen precipitously between assessments. Even with frequent monitoring, some patients will develop severe vision loss. -
MRI (Infants Only)
As clinically indicated during treatment in infants with IS
Trigger-based Abnormal T2 signal changes in thalamus, basal ganglia, brainstem, and cerebellum reported in 22% of vigabatrin-treated infants. Generally resolve with discontinuation. Not required for adults as there is no evidence vigabatrin causes MRI changes in this population. -
Complete Blood Count
Periodically during therapy
Routine Anemia occurs in 6% vs 2% placebo. Mean hemoglobin decrease ~3%. Monitor for symptoms of anemia (fatigue, pallor, dyspnea). -
Body Weight
Each visit
Routine Weight gain ≥7% in 17% adults, 47% pediatric CPS patients. Monitor nutritional counseling and metabolic parameters. -
Mood and Suicidality
Every visit, ongoing
Routine AED class warning for suicidal behavior and ideation. Monitor for depression, unusual mood/behavioral changes. -
Peripheral Neuropathy Assessment
Periodically; if symptoms develop
Trigger-based Numbness, tingling in toes/feet, decreased vibration/position sense, progressive loss of ankle reflexes. Occurred in 4.2% of patients in pooled studies. Reversibility not established. -
Renal Function
Baseline and periodically
Routine Vigabatrin is primarily renally eliminated. Dose reduction required in renal impairment (mild −25%, moderate −50%, severe −75%). Monitor CrCl, especially in elderly patients or those with changing renal function. -
Treatment Response Assessment
CPS: within 3 months of initiation; IS: within 2–4 weeks
Routine Mandatory per FDA PI. Withdraw vigabatrin if no substantial clinical benefit by these timepoints. Patient response and continued need for treatment must be periodically reassessed. Every additional day of unnecessary exposure increases cumulative vision loss risk.
Contraindications & Cautions
Absolute Contraindications
- None listed in the FDA PI — the FDA label states no absolute contraindications. However, the extensive warnings and REMS program effectively restrict use to situations where benefits clearly outweigh the risk of permanent vision loss.
Relative Contraindications (Specialist Input Recommended)
- Pre-existing visual field defects or other irreversible vision loss — the interaction of existing vision damage with vigabatrin-induced damage is likely adverse and not well characterized; benefits must clearly outweigh risks
- Concurrent use of other drugs with serious ophthalmic effects (retinopathy, glaucoma) — additive vision risk; avoid unless benefits clearly outweigh risks
- Severe renal impairment (CrCl 10–30 mL/min) — 75% dose reduction required; drug accumulation risk
- Pregnancy — animal data show fetal harm (cleft palate in rabbits at doses near therapeutic range); use only if potential benefits justify potential risks
Use with Caution
- Nursing mothers — vigabatrin is excreted in human breast milk; breastfeeding is not recommended
- Elderly patients — delayed absorption, increased peak concentration, and prolonged half-life due to decreased renal clearance; start with reduced doses
- History of depression or psychiatric illness — AED class warning; rare psychosis reported, more common in adults than children
- Patients at risk of generalized tonic-clonic seizures — vigabatrin approved only for focal (CPS) and IS; not for primary generalized epilepsy
SABRIL can cause permanent bilateral concentric visual field constriction, including tunnel vision that can result in disability. In some cases, SABRIL also can damage the central retina and may decrease visual acuity. The onset of vision loss is unpredictable, and can occur within weeks of starting treatment or at any time during or after treatment. The risk increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk. Vision loss due to SABRIL is not reversible. Because of this risk, SABRIL is available only through the Vigabatrin REMS Program.
Antiepileptic drugs, including SABRIL, increase the risk of suicidal thoughts or behavior. Pooled analysis of 199 placebo-controlled trials of 11 AEDs showed approximately twice the risk (adjusted RR 1.8; 95% CI: 1.2–2.7) in AED-treated patients compared to placebo. Monitor all patients for emergence or worsening of depression, suicidal thoughts, or unusual changes in behavior.
Patient Counselling
Purpose of Therapy
Vigabatrin is a seizure medication that works by increasing the levels of a natural calming chemical (GABA) in the brain. It is used for two specific conditions: infantile spasms in babies (1 month to 2 years) and hard-to-treat focal seizures in patients 2 years and older who have not responded to other seizure medicines. Because vigabatrin carries a risk of permanent vision changes, it is only prescribed when the benefits are expected to outweigh this serious risk.
How to Take
Vigabatrin can be taken with or without food. Tablets should be taken twice daily. For infants and young children, the powder packets must be dissolved in cold or room-temperature water (10 mL per packet) to create a liquid solution (50 mg/mL), which is then measured with an oral syringe. Each dose must be prepared fresh and any unused solution discarded. Do not stop this medication suddenly — your doctor will gradually reduce the dose over several weeks.
Sources
- SABRIL (vigabatrin) Tablets and Oral Solution. Full Prescribing Information. NDA 020427/S-025, 022006/S-026. Lundbeck Inc. Revised October 2021. FDA Label Primary US prescribing information for vigabatrin (Sabril), including the Black Box Warning for vision loss, REMS requirements, weight-based pediatric dosing tables, and complete adverse reactions data from controlled trials.
- VIGAFYDE (vigabatrin) Oral Solution. Full Prescribing Information. NDA 217684. Revised 2024. FDA Label Prescribing information for the Vigafyde formulation, providing additional pharmacokinetic data including infant Tmax (~2.5 hours) and food effect data.
- Elterman RD, Shields WD, Mansfield KA, Nakagawa J; US Infantile Spasms Vigabatrin Study Group. Randomized trial of vigabatrin in patients with infantile spasms. Neurology. 2001;57(8):1416–1421. doi:10.1212/WNL.57.8.1416 Pivotal US randomized trial demonstrating vigabatrin efficacy for infantile spasms, supporting FDA approval.
- French JA, Mosier M, Walker S, Sommerville K, Sussman N; Vigabatrin Protocol 024 Investigative Cohort. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology. 1996;46(1):54–61. doi:10.1212/WNL.46.1.54 Key placebo-controlled trial establishing vigabatrin 3 g/day efficacy for refractory CPS in adults.
- Chiron C, Dumas C, Jambaque I, Mumford J, Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res. 1997;26(2):389–395. doi:10.1016/S0920-1211(96)01006-6 Landmark study demonstrating vigabatrin superiority over hydrocortisone for infantile spasms in tuberous sclerosis complex (TSC), with high response rates in this population.
- Go CY, Mackay MT, Weiss SK, et al; Child Neurology Society. Evidence-based guideline update: medical treatment of infantile spasms. Neurology. 2012;78(24):1974–1980. doi:10.1212/WNL.0b013e318259e2cf AAN/CNS guideline establishing vigabatrin as a Level B treatment for infantile spasms (possibly effective) and Level C for TSC-related spasms.
- Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551–563. doi:10.1111/epi.12074 ILAE evidence review of ASM efficacy; vigabatrin assessed for infantile spasms and refractory focal epilepsy.
- Jung MJ, Lippert B, Metcalf BW, Böhlen P, Schechter PJ. γ-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem. 1977;29(5):797–802. doi:10.1111/j.1471-4159.1977.tb10721.x Original description of vigabatrin (γ-vinyl GABA) as a selective irreversible inhibitor of GABA-transaminase, establishing its mechanism of action.
- Duboc A, Hanoteau N, Simonutti M, et al. Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats. Ann Neurol. 2004;55(5):695–705. doi:10.1002/ana.20081 Key study demonstrating the retinal toxicity mechanism of vigabatrin, showing cone photoreceptor damage and taurine depletion as the likely basis for visual field loss.
- Vigabatrin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. StatPearls Comprehensive clinical pharmacology reference covering mechanism of action, dosing, pharmacokinetics, vision loss risk, and monitoring requirements.
- Rey E, Pons G, Olive G. Vigabatrin: clinical pharmacokinetics. Clin Pharmacokinet. 1992;23(4):267–278. doi:10.2165/00003088-199223040-00003 Definitive pharmacokinetic review establishing vigabatrin PK parameters: Vd ~0.8 L/kg, zero protein binding, half-life 5.3–7.4 hours, ~70% renal excretion unchanged, and linear dose-proportional kinetics.
- Krauss G, Faught E, Foroozan R, et al. Sabril registry 5-year results: characteristics of adult patients treated with vigabatrin. Epilepsy Behav. 2016;56:15–19. doi:10.1016/j.yebeh.2015.12.025 Sabril post-marketing registry providing long-term safety data on vision monitoring and visual field outcomes in adult patients treated with vigabatrin.